Eupraxia Pharmaceuticals Inc
EPRX5.310USD
+0.050+0.95%
Market hours （ET）Quotes delayed by 15 min
190.36MMarket Cap
LossP/E TTM
More Details of Eupraxia Pharmaceuticals Inc Company
Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products. The Company’s lead product candidate, EP-104, is designed to address the significant unmet medical need and market demand for conditions where long-lasting symptom relief is essential to effective treatment. The primary targets for EP-104 have been identified as knee osteoarthritis (OA) and eosinophilic esophagitis (EoE). The product in development for OA is called EP-104IAR and the product in development in EoE is called EP-104GI. DiffuSphere, a proprietary, polymer based micro-sphere technology, is designed to facilitate targeted drug delivery, with extended duration of effect, and offers multiple, highly tunable pharmacokinetic (PK) profiles.
Company Info
Ticker SymbolEPRX
Company nameEupraxia Pharmaceuticals Inc
IPO dateMar 09, 2021
CEODr. James A. Helliwell, M.D.
Number of employees33
Security typeOrdinary Share
Fiscal year-endMar 09
Address201-2067 Cadboro Bay Rd.
CityVICTORIA
Stock exchangeThe Toronto Stock Exchange
CountryCanada
Postal codeV8R 5G4
Phone12505903968
Websitehttps://eupraxiapharma.com/home/default.aspx
Ticker SymbolEPRX
IPO dateMar 09, 2021
CEODr. James A. Helliwell, M.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
224.87K
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
13.93K
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Mr. Paul A. Brennan
Mr. Paul A. Brennan
Chief Business Officer
Chief Business Officer
--
--
Mr. Alexander Rothwell
Mr. Alexander Rothwell
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Simon Pimstone, M.D., Ph.D.
Dr. Simon Pimstone, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Paul Geyer
Mr. Paul Geyer
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Michael Wilmink, M.D.
Dr. Michael Wilmink, M.D.
Independent Director
Independent Director
224.87K
--
Dr. Amanda Malone
Dr. Amanda Malone
Chief Operating and Scientific Officer
Chief Operating and Scientific Officer
46.34K
+18.22%
Richard M. Glickman ,
Richard M. Glickman ,
Independent Director
Independent Director
13.93K
--
Mr. Adam Peeler
Mr. Adam Peeler
Investor relations
Investor relations
--
--
Mr. Joseph Freedman
Mr. Joseph Freedman
Independent Director
Independent Director
--
--
Mr. John S. Montalbano
Mr. John S. Montalbano
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Mon, Jun 2
Updated: Mon, Jun 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Disbrow (Robert)
8.04%
Scotia Capital Inc.
4.32%
Freedman (Joseph S)
4.20%
Montalbano (John S.)
3.37%
Helliwell (James Allen)
1.87%
Other
78.19%
Shareholders
Shareholders
Proportion
Disbrow (Robert)
8.04%
Scotia Capital Inc.
4.32%
Freedman (Joseph S)
4.20%
Montalbano (John S.)
3.37%
Helliwell (James Allen)
1.87%
Other
78.19%
Shareholder Types
Shareholders
Proportion
Individual Investor
19.13%
Research Firm
4.43%
Investment Advisor
1.64%
Hedge Fund
0.03%
Other
74.78%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
27
9.07M
25.23%
+3.18M
2025Q1
33
13.45M
37.66%
+9.00M
2024Q4
29
12.81M
35.95%
+8.38M
2024Q3
26
11.48M
34.74%
+5.59M
2024Q2
21
8.52M
26.42%
+4.35M
2024Q1
12
3.99M
17.06%
-637.88K
2023Q4
16
7.00M
38.32%
+2.38M
2023Q3
16
7.01M
38.38%
+2.38M
2023Q2
15
6.89M
39.05%
+2.27M
2023Q1
16
6.89M
40.01%
+2.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Disbrow (Robert)
2.89M
8.04%
+2.89M
--
Sep 30, 2024
Scotia Capital Inc.
1.55M
4.32%
+160.96K
+11.57%
Mar 31, 2025
Freedman (Joseph S)
1.51M
4.2%
+10.00K
+0.67%
Jun 18, 2025
Montalbano (John S.)
1.21M
3.37%
--
--
Apr 25, 2025
Helliwell (James Allen)
674.01K
1.87%
--
--
Apr 25, 2025
Geyer (Paul L)
340.35K
0.95%
--
--
Apr 25, 2025
Wilmink (Michael)
224.87K
0.63%
--
--
Apr 25, 2025
RBC Dominion Securities, Inc.
206.63K
0.57%
+59.68K
+40.62%
Mar 31, 2025
RBC Phillips, Hager & North Investment Counsel Inc.
136.20K
0.38%
--
--
Mar 31, 2025
TD Waterhouse Canada, Inc.
104.99K
0.29%
+104.99K
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
